Make the
liquid biopsy
of circulating tumor cells accessible to everyone
OUR MISSION
Découvrez nos collections exclusives
Écrivez un ou deux paragraphes décrivant votre produit ou vos services. Pour réussir, votre contenu doit être utile à vos lecteurs.
Des solutions sur mesure
La satisfaction client est notre priorité. Notre équipe d'assistance est toujours prête à vous aider et à vous garantir une expérience réussie.
Qualité et Excellence
Forts d'une vaste expérience et d'une connaissance approfondie du secteur, nous fournissons des informations et des solutions qui vous permettent de garder une longueur d'avance.
Do you know what are cancer care delivery challenges these days ?
Diagnosis based on the analysis of a single‐tumor biopsy only reflects a single point in time of the whole intratumoral heterogeneity.
The alternative:
Liquid biopsy arises as a minimally invasive approach offering increased temporal and spatial representativeness of the heterogeneity of solid tumors, enabling real-time monitoring of the disease and personalization of the therapeutic project.
Circulating Tumor Cells (CTC) travel in every patient's bloodstream. CTC are the physical vectors of cancer aggressiveness and metastatic potential. Rare (1/1 billion normal blood cells), they are also difficult to capture while maintaining their physiological integrity.
Accelerate cancer characterization through liquid biopsy
SmartCatch is lifting the current locks on CTC liquid biopsy by developing a range of compact, portable, easy-to-use products adapted to a use in clinical routine, in order to make the liquid biopsy of CTC accessible and the essential medical procedure for the diagnosis, follow-up and personalization of care in medical oncology.
INNOVATION
Our solutions
SmartCatch's know-how is based on the design and manufacture of cutting-edge microfiltration devices allowing the isolation of CTC directly from whole blood with no pre-analytical steps involved. Ultimately, this will help researchers and clinicians gain access to valuable data that will improve the quality of cancer patient outcome.
INNOVATION
Our vision
SmartCatch’s vision is to become a pioneer in the field of cancer diagnosis and to make liquid biopsy accessible to everyone.
Our mission
SmartCatch pioneers the convergence of cutting-edge microtechnologies with the expansive realm of Circulating Tumor Cells (CTCs), ushering in a new era in precision medicine.
We are dedicated to transforming cancer care with a personalized touch. Our commitment extends to empowering clinicians, pharmaceutical companies, and researchers worldwide with advanced devices that delve into the intricate realms of multi-omic characterization of CTCs.
In doing so, we strive to provide a comprehensive understanding of the multifaceted nature of cancer, enriching the landscape of research and clinical practices globally.
Isolated cells on capture device consumable
